-
Several commonly used photosensitizing antihypertensive drugs can confer as much as a four-fold increase in the risk of lip cancer when prescribed long-term in non-Hispanic whites.
-
-
The FDA has approved a second oral drug for the treatment of multiple sclerosis (MS). Teriflunomide, a metabolite of leflunomide and a pyrimidine synthesis inhibitor, is an immunomodulatory agent. It is marketed by Sanofi Aventis as Aubagio.
-
-
In November 2011, the Centers for Disease Control and Prevention presented data on emergency hospitalizations because of adverse drug reactions. The report showed that insulin and oral hypoglycemic agents caused nearly 25% of the medication-induced hospitalizations in older adults in the United States.
-
REM behavior disorder can be reliably diagnosed using a simple bed-partner questionnaire and its presence is a risk factor for a future neurodegenerative disease.
-
-
Preliminary trials of low-dose intranasal insulin suggest a possible benefit that warrants further investigation.
-
Statins and diabetes risk; new treatment guideline for diabetes; new pertussis vaccine recommendation; antibiotics and rhinosinusitis; fluoroquinolones and cystitis; and FDA actions.
-
Necrotizing myositis is a newly described inflammatory myopathy that has an autoimmune etiology and may be associated with anti-signal recognition particle autoantibodies.
